The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and chemotherapy in patients with pancreatic ductal adenocarcinoma.
At a 3.2-year median follow up, the eight patients who had developed T cell responses from the vaccine had not reached their median recurrence-free survival. In comparison, the eight patients who did not develop the immune responses saw their cancer return after a median of 13.4 months. The vaccine-induced CD8+ T cells that help fight cancer were found to have long lifespans, with some remaining active three years following vaccination.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
